Aquestive Therapeutics. has been granted a patent for a pharmaceutical composition that features a polymeric matrix designed to enhance the permeation of active components, specifically including epinephrine or its salts/esters, along with an adrenergic receptor interactor. GlobalData’s report on Aquestive Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aquestive Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Aquestive Therapeutics's grant share as of June 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Enhanced pharmaceutical compositions for active component permeation
The granted patent US12023309B2 outlines a pharmaceutical composition that integrates a polymeric matrix with a pharmaceutically active component, specifically epinephrine or its acceptable salts or esters, alongside an adrenergic receptor interacter. The claims detail various forms of the adrenergic receptor interacter, including compounds such as farnesol, linoleic acid, eugenol, and various phytoextracts, particularly those derived from clove plants. The composition can be formulated in multiple dosage forms, including chewable tablets, gels, creams, and films, and may incorporate a range of polymeric materials, such as mucoadhesive polymers, cellulosic polymers, and polyethylene oxide.
Additionally, the patent describes methods for creating the pharmaceutical composition, emphasizing the combination of the adrenergic receptor interacter with the active component within the polymeric matrix. The claims also mention the potential inclusion of stabilizers and other excipients to enhance the formulation's efficacy and stability. The versatility of the composition is highlighted by the inclusion of various polymers and the option to contain the active components in discrete layers within a film. Overall, this patent presents a comprehensive approach to developing a pharmaceutical formulation that leverages the synergistic effects of epinephrine and adrenergic receptor interacters for therapeutic applications.
To know more about GlobalData’s detailed insights on Aquestive Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
